Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence
Primary Purpose
Asthma
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Dulera
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring Adherence monitoring, Motivational Interviewing Adherence strategies
Eligibility Criteria
Inclusion Criteria:
- Physician diagnosis of asthma of moderate severity
- Subjects ≥ 18 years of age
- Currently receiving an inhaled corticosteroid medication and being prescribed Dulera 100/5 as part of standard of care based upon asthma severity and dosing guidelines
- Asthma Control Questionnaire (ACQ) result > 1.0 at entry
- Demonstration of correct inhalation technique for use of meter-dosed inhalers (MDIs)
- History of reversible airway obstruction documented by treating physician Exclusion Criteria: intermittent asthma; emphysema, chronic obstructive pulmonary disease; chronic bronchitis; cystic fibrosis; medication that may have a drug interaction with Dulera
Exclusion Criteria
- Intermittent asthma (asthma exacerbations or symptoms < 3 days/week)
- Diagnosis of emphysema in prior year
- Diagnosis at any time of: chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis, bronchiectasis, Churg Strauss, Wegener's, sarcoidosis, pulmonary hypertension or lung cancer
- On any medication documented to have a drug interaction with Dulera
Sites / Locations
- West Penn Allegheny Health System
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Dulera adherence monitoring
Dulera Standard of Asthma Care
Arm Description
Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence
Dulera standard of asthma care
Outcomes
Primary Outcome Measures
Asthma Control
Asthma Control Questionnaire measured at each office visit. ACQ integrates values by 6 clinical questions related to symptoms and the value related to FEV1% predicted with a total score ranging from 0-6 and higher values indicating poorer asthma control.
Secondary Outcome Measures
Adherence to Dulera 100/5 and 200/5
Subjects in the monitoring group will have adherence greater than or equal to the 60% benchmark
Adherence was calculated by taking the number of doses actually taken divided by the number of doses prescribed and multiplying by 100.
Overall Adherence to Dulera 100/5 and 200/5
Subjects in the monitoring group will have adherence greater than or equal to the 60% benchmark
Overall interval value was the mean of daily percent
Full Information
NCT ID
NCT02045875
First Posted
January 23, 2014
Last Updated
June 19, 2018
Sponsor
Asthma Management Systems
Collaborators
Merck Sharp & Dohme LLC, West Penn Allegheny Health System
1. Study Identification
Unique Protocol Identification Number
NCT02045875
Brief Title
Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence
Official Title
Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence
Study Type
Interventional
2. Study Status
Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
March 4, 2014 (Actual)
Primary Completion Date
July 1, 2017 (Actual)
Study Completion Date
July 12, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Asthma Management Systems
Collaborators
Merck Sharp & Dohme LLC, West Penn Allegheny Health System
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
40 subjects with moderate-to-severe asthma will be randomly selected for study in which 20, will be monitored for medication use (Dulera 100/5, Dulera 200/5 and Proventil HFA) over 3 months. These intervention subjects will receive medication use feedback at each visit, while the control group will receive the standard of asthma care. Those interventional subjects with Dulera adherence<60% will receive feedback based on an asthma adherence disease management model protocol, Asthma Adherence Pathway. Intervention clinicians will been trained in Motivational Interviewing to reduce subject ambivalence about medication use. The primary hypothesis is that subjects who receive medication monitoring and Motivational Interviewing adherence strategies will have better asthma control, as measured by the Asthma Control Questionnaire, than the control group.
Detailed Description
Primary Clinical Hypothesis: Poorly controlled subjects with moderate-to-severe asthma (measured by Asthma Control Questionnaire (ACQ) ≥ 1) despite treatment with Dulera, who are treated with the asthma adherence disease management protocol, Asthma Adherence Pathway™, will achieve greater asthma control than similar control subjects who are treated with the current standard of care.
Primary end point: There will be four measures of Asthma Control Questionnaire (ACQ) over time over 3 months. The primary endpoint is the third month measure of ACQ.
Secondary Clinical Hypothesis: The asthma adherence disease management program, Asthma Adherence Pathway™, will increase observed adherence to Dulera relative to a benchmark of 60% adherence (i.e., expected prescribed actuations).
Secondary end points: a) Average adherence to Dulera over the three month study period
Tertiary Clinical Hypothesis: Responses to Adult Asthma Adherence Questionnaire (AAAQ) will be related to Dulera Adherence
Tertiary Study Endpoints: There will be 2 measures of the AAAQ (first and last visit) and the tertiary endpoint is the last visit
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Adherence monitoring, Motivational Interviewing Adherence strategies
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Dulera adherence monitoring
Arm Type
Experimental
Arm Description
Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence
Arm Title
Dulera Standard of Asthma Care
Arm Type
Active Comparator
Arm Description
Dulera standard of asthma care
Intervention Type
Drug
Intervention Name(s)
Dulera
Other Intervention Name(s)
mometasone furoate/formoterol fumarate dihydrate
Intervention Description
Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.
Primary Outcome Measure Information:
Title
Asthma Control
Description
Asthma Control Questionnaire measured at each office visit. ACQ integrates values by 6 clinical questions related to symptoms and the value related to FEV1% predicted with a total score ranging from 0-6 and higher values indicating poorer asthma control.
Time Frame
Baseline, one, two and three months
Secondary Outcome Measure Information:
Title
Adherence to Dulera 100/5 and 200/5
Description
Subjects in the monitoring group will have adherence greater than or equal to the 60% benchmark
Adherence was calculated by taking the number of doses actually taken divided by the number of doses prescribed and multiplying by 100.
Time Frame
week 2. months 1, 2, and 3
Title
Overall Adherence to Dulera 100/5 and 200/5
Description
Subjects in the monitoring group will have adherence greater than or equal to the 60% benchmark
Overall interval value was the mean of daily percent
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Physician diagnosis of asthma of moderate severity
Subjects ≥ 18 years of age
Currently receiving an inhaled corticosteroid medication and being prescribed Dulera 100/5 as part of standard of care based upon asthma severity and dosing guidelines
Asthma Control Questionnaire (ACQ) result > 1.0 at entry
Demonstration of correct inhalation technique for use of meter-dosed inhalers (MDIs)
History of reversible airway obstruction documented by treating physician Exclusion Criteria: intermittent asthma; emphysema, chronic obstructive pulmonary disease; chronic bronchitis; cystic fibrosis; medication that may have a drug interaction with Dulera
Exclusion Criteria
Intermittent asthma (asthma exacerbations or symptoms < 3 days/week)
Diagnosis of emphysema in prior year
Diagnosis at any time of: chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis, bronchiectasis, Churg Strauss, Wegener's, sarcoidosis, pulmonary hypertension or lung cancer
On any medication documented to have a drug interaction with Dulera
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Deborah Gentile, DO
Organizational Affiliation
West Penn Allegheny Health System
Official's Role
Principal Investigator
Facility Information:
Facility Name
West Penn Allegheny Health System
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15212
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence
We'll reach out to this number within 24 hrs